HRP20000541A2 - PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY - Google Patents

PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Info

Publication number
HRP20000541A2
HRP20000541A2 HR20000541A HRP20000541A HRP20000541A2 HR P20000541 A2 HRP20000541 A2 HR P20000541A2 HR 20000541 A HR20000541 A HR 20000541A HR P20000541 A HRP20000541 A HR P20000541A HR P20000541 A2 HRP20000541 A2 HR P20000541A2
Authority
HR
Croatia
Prior art keywords
hmg
coa reductase
reductase inhibitor
crystallization
water
Prior art date
Application number
HR20000541A
Other languages
English (en)
Inventor
Pflaum Zlatko
Milivojevič Duuean
Senica David
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000541(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of HRP20000541A2 publication Critical patent/HRP20000541A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
HR20000541A 1998-02-18 1999-02-17 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY HRP20000541A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800046A SI9800046A (sl) 1998-02-18 1998-02-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
PCT/IB1999/000808 WO1999042601A1 (en) 1998-02-18 1999-02-17 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Publications (1)

Publication Number Publication Date
HRP20000541A2 true HRP20000541A2 (en) 2001-12-31

Family

ID=20432203

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000541A HRP20000541A2 (en) 1998-02-18 1999-02-17 PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Country Status (21)

Country Link
US (1) US6825015B1 (cs)
EP (1) EP1054993B1 (cs)
JP (2) JP2002504345A (cs)
KR (1) KR100582620B1 (cs)
CN (1) CN1206363C (cs)
AT (1) ATE296357T1 (cs)
AU (1) AU743619B2 (cs)
BG (1) BG64289B1 (cs)
CA (1) CA2321052A1 (cs)
CZ (1) CZ297093B6 (cs)
DE (1) DE69925459T2 (cs)
HR (1) HRP20000541A2 (cs)
HU (1) HUP0100820A3 (cs)
IL (1) IL137782A0 (cs)
PL (1) PL193510B1 (cs)
RO (1) RO120922B1 (cs)
RU (1) RU2235130C2 (cs)
SI (2) SI9800046A (cs)
SK (1) SK285074B6 (cs)
WO (1) WO1999042601A1 (cs)
YU (1) YU50100A (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02005283A (es) * 1999-11-30 2003-10-06 Biogal Gyogyszergyar Proceso para recuperar compuestos estatina de un caldo de fermentacion.
CZ20021998A3 (cs) 1999-12-14 2003-02-12 Biogal Gyogyszergyar Rt. Nové formy sodné soli pravastatinu
AU2001236543B2 (en) * 2000-02-24 2005-02-03 Teva Gyogyszergyar Reszvenytarsasag Method of purifying a fermentation broth
PL357533A1 (en) 2000-03-03 2004-07-26 Plus Chemicals, S.A. A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities
IN192861B (cs) * 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
RU2261901C2 (ru) * 2003-10-17 2005-10-10 Буяновский Эдуард Константинович Штамм гриба aspergillus terreus № 44-62 - продуцент ловастатина, промышленный способ выделения ловастатина и способ лактонизации статинов
PL1641447T3 (pl) 2003-11-24 2009-04-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania prawastatyny
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN102384955B (zh) * 2010-09-01 2014-04-30 北京北大维信生物科技有限公司 人体血浆中HMG－CoA还原酶抑制剂的定量分析方法
RU2585234C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Способ получения компактина
RU2585233C2 (ru) * 2013-12-27 2016-05-27 Открытое акционерное общество "Красфарма" Промышленный способ получения компактина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294846A (en) * 1979-09-21 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and products of preparation
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
JPH11501218A (ja) * 1995-08-03 1999-02-02 ギスト ブロカデス ベスローテン フェンノートシャップ アシル化された化合物の脱アシル化の選択的方法
ES2131037T3 (es) 1995-12-06 2001-12-16 Balkanpharma Razgrad Ad Procedimiento de preparacion de lovastatina.
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására

Also Published As

Publication number Publication date
CZ297093B6 (cs) 2006-09-13
DE69925459D1 (de) 2005-06-30
BG104696A (en) 2001-07-31
AU3438499A (en) 1999-09-06
US6825015B1 (en) 2004-11-30
RO120922B1 (ro) 2006-09-29
SK11852000A3 (sk) 2001-05-10
YU50100A (sh) 2003-07-07
PL193510B1 (pl) 2007-02-28
KR20010041024A (ko) 2001-05-15
EP1054993A1 (en) 2000-11-29
WO1999042601A1 (en) 1999-08-26
HUP0100820A2 (hu) 2001-08-28
JP2002504345A (ja) 2002-02-12
SI9800046A (sl) 1999-08-31
JP2005110693A (ja) 2005-04-28
HUP0100820A3 (en) 2003-07-28
KR100582620B1 (ko) 2006-05-23
CA2321052A1 (en) 1999-08-26
IL137782A0 (en) 2001-10-31
DE69925459T2 (de) 2006-04-27
ATE296357T1 (de) 2005-06-15
PL342513A1 (en) 2001-06-18
RU2235130C2 (ru) 2004-08-27
EP1054993B1 (en) 2005-05-25
AU743619B2 (en) 2002-01-31
CN1291238A (zh) 2001-04-11
SK285074B6 (sk) 2006-05-04
CN1206363C (zh) 2005-06-15
SI1054993T1 (en) 2005-10-31
CZ20002856A3 (cs) 2000-11-15
BG64289B1 (bg) 2004-08-31

Similar Documents

Publication Publication Date Title
HRP20000541A2 (en) PROCESS FOR THE OBTAINING OF HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
AU5949294A (en) 1H-indole-3-acetamide sPLA2 inhibitors
CA2393057A1 (en) Process for recovering pravastatin from a fermentation broth
RU2000124064A (ru) Способ получения ингибиторов hmg-coa-редуктазы высокой степени чистоты
AU2003290147A1 (en) High purity phthalein derivatives and method for preparing same
DK1216237T3 (da) Proces til fremstilling af mycophenolsyre og derivater deraf
EP0803576A3 (en) Process for the production of lipstatin and tetrahydrolipstatin
EP0927755A3 (en) Haloaccloacetate reductase, method for producing said enzyme, and method for producing alcohols using said enzyme
AU7432198A (en) Improved process for the fermentative production of penicillin
DK0698111T3 (da) Fremgangsmåde til syntese af HMG-CoA-reduktaseinhibitorer
AU3419399A (en) Novel process for the fermentative production of cephalosporin
AU547968B2 (en) Ml-236b derivatives i.e. alactone and the corresponding free hydroxy-carboxylic acid
ES2001410A6 (es) Un procedimiento para la preparacion de nuevos derivados de clavam, utiles para la preparacion de acido clavulanico, e intermedios de los mismos.
US5258290A (en) Fermentation process for the production of β-carboline derivatives by Myrothecium verrucaria
WO2004020650A3 (en) An enzymatic process for preparing beta-lactams
PL330706A1 (en) Improved method of obtaining cephalosporin by fermentation process
JPS57141296A (en) Fermentation method
NO20045513L (no) Fremgangmate for fremstiling av konjugert linolsyre
WO2000052012A3 (en) A method for synthesizing porphyrin compounds
SU680657A3 (ru) Способ получени антибиотика, обладающего антибактериальным действием против грамположительных бактерий
DK0663957T3 (da) Fremgangsmåde til fermentativ fremstilling af 2-hydroxyphenyleddikesyre
WO2009078033A4 (en) Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
EP0795607A3 (en) Process for the preparation of a lactone
KR940014801A (ko) 미생물이 생산하는 리보플라빈의 제조방법
JP3917723B2 (ja) ラクトン加水分解酵素およびその製造法

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090216

Year of fee payment: 11

ODBC Application rejected